scholarly journals The Use of NeuroAiD (MLC601) in Postischemic Stroke Patients

2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Jose C. Navarro ◽  
Mark C. Molina ◽  
Alejandro C. Baroque II ◽  
Johnny K. Lokin
Keyword(s):  
Functional Recovery ◽  
Randomized Control Trial ◽  
Retrospective Cohort ◽  
Data Bank ◽  
Modified Rankin Scale ◽  
Stroke Patients ◽  
Open Label ◽  
Large Randomized Control Trial ◽  
Randomized Control ◽  
Stroke Data Bank

Aim. We aimed to assess the efficacy of MLC601 on functional recovery in patients given MLC601 after an ischemic stroke.Methods. This is a retrospective cohort study comparing poststroke patients given open-label MLC601 (; 9 female) for three months and matching patients who did not receive MLC601 from our Stroke Data Bank. Outcome assessed was modified Rankin Scale (mRS) at three months and analyzed according to: (1) achieving a score of 0-2, (2) achieving a score of 0-1, and (3) mean change in scores from baseline.Results. At three months, 21 patients on MLC601 became independent as compared to 17 patients not on MLC601 (OR 1.79; 95% CI 0.62–5.2; ). There were twice as many patients () on MLC601 who attained mRS scores similar to their prestroke state than in the non-MLC601 group () (OR 3.14; 95% CI 1.1–9.27; ). Mean improvement in mRS from baseline was better in the MLC601 group than in the non-MLC601 group (−1.7 versus −0.9; mean difference −0.73; 95% CI −1.09 to −0.38; ).Conclusion. MLC601 improves functional recovery at 3 months postischemic stroke. An ongoing large randomized control trial of MLC601 will help validate these results.

scholarly journals Effect of pentoxifylline on histological activity and fibrosis of nonalcoholic steatohepatitis patients: A one year randomized control trial

2017 ◽  
Vol 5 (3) ◽  
pp. 155-163 ◽  
Author(s):  
Shahinul Alam ◽  
SKM Nazmul Hasan ◽  
Golam Mustafa ◽  
Mahabubul Alam ◽  
Mohammad Kamal ◽  
...  
Keyword(s):  
Fatty Liver ◽  
Nonalcoholic Steatohepatitis ◽  
Randomized Control Trial ◽  
Lifestyle Modification ◽  
Control Group ◽  
Open Label ◽  
Histological Activity ◽  
Randomized Control ◽  
One Year ◽  
Lobular Inflammation

AbstractBackground and ObjectivesTo observe the effect of Pentoxifylline for 1 year on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis (NASH).Materials and MethodsA single center, open label Randomized Control Trial. Patients were included if they had ultrasonographic evidence of fatty liver and nonalcoholic fatty liver disease activity score (NAS) ≥ 5 on liver histology. A total of 35 patients were selected; 25 of PL (Experimental) group and 10 of L (Control) group. PL group received 400 mg pentoxifylline thrice daily along with lifestyle modification and there was only lifestyle modification for the L group. After one year, NAS and fibrosis was compared in both groups.ResultsIn PL group, NAS improved 2.10 ± 1.07; whereas in L group, NAS was 0.90 ± 0.99 (P = 0.006). As per the protocol analysis, NAS ≥ 2 improved in 15/20 (75%) in PL group and in 3/10 (30%) in L group (P = 0.018). In PL group, the individual component of NAS, steatosis improved from 2.30 ± 0.66 to 0.95 ± 0.76 (P = 0.000), lobular inflammation from 1.65 ± 0.59 to 1.05 ± 0.51 (P = 0.002) and hepatocyte ballooning from 1.50 ± 0.51 to 1.30 ± 0.57 (P = 0.258). In L group, steatosis improved from 2.30 ± 0.68 to 1.40 ± 1.08 (P = 0.01), lobular inflammation and hepatocyte ballooning did not improve. The fibrosis score did not improve in any group. In PL group, NAS improved significantly (P = 0.027; OR=22.76, CI=1.43-362.40) independent of weight reduction.ConclusionPentoxifylline for 1 year improves the hepatic histological activity but not fibrosis of NASH patients.

Sign in / Sign up

Export Citation Format

Share Document